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The proper supply of folate during the preconception 
period, pregnancy and lactation largely determines the 
proper development and growth of the fetus and new-
born infant. Foliates is among the most essential elements 
of fast-dividing cells as it plays an important role in DNA 
synthesis. An increased demand for folate, which is not syn-
thesized in the human body, during pregnancy can be met 
only partially by the supply of foods rich in folate — about 
150–250 µg [1]. Folate deficiency is associated with a higher 
risk of neural tube defects in the fetus, as well as cleft lip 
and palate and Down syndrome [2]. Disorders of folate 
metabolism can lead to hyperhomocysteinaemia and more 
frequent complications of pregnancy, such as recurrent 
miscarriage, intrauterine growth restriction (IUGR) and pre-
eclampsia [3, 4].
FOLATE SUPPLEMENTATION 
Randomized and cohort studies conducted in the 1980s 
and 1990s show that folic acid supplementation significantly 
reduces the risk of neural tube defects [5–12]. The follow-
-up observations also indicate that folate supplementation 
reduces the occurrence of heart defects, urinary tract de-
fects, limb defects, cleft lip and palate and preeclampsia 
[3, 4, 13–15].
Recent studies have shown that 12-week supplemen-
tation is necessary in the preconception period to achieve 
adequate red blood cell folate concentration [16, 17].
Folic acid consumed in the form of vitamin supplements 
must undergo a number of biochemical reactions to reach 
its active form — 5-methyltetrahydrofolate. Vitamin B12 is 
one of the important cofactors of these changes. Vitamin 
B12 deficiency is particularly unfavourable with high folate 
concentrations [18]. The resulting disorders in the conver-
sion of homocysteine to methionine lead to hyperhomo-
cysteinemia, which increases the risk of pregnancy com-
plications. Unmetabolized folic acid in the blood can have 
a negative effect on the human body, as it may affect the 
activity of natural killer cells and the immune system [19]. 
Accumulation of unmetabolized folic acid can be avoided by 
supplementation with appropriate doses and active folate 
forms. High doses of folic acid may increase the risk of fetal 
damage in early pregnancy, as well as obesity, insulin resi-
stance and type 2 diabetes in the later life of the offspring 
[20]. The supplementation dose should be determined ba-
sed on factors that increase the risk of folate deficiency and 
fetal defects. The preparations used should also contain 
vitamin B12. 
Recommendations
• All women of childbearing age should include in 
their diet foods rich in folate (lettuce, spinach, cab-
bage, broccoli, whole grains, liver, eggs, nuts and 
cheeses) and fortified foods. (Level B)
• When planning a pregnancy, women of childbearing 
age should additionally use folate supplementation 
for at least 12 weeks before conception. (Level B)
• Women should continue to use folate supplementa-
tion throughout their pregnancy, puerperium and 
lactation period. They should use preparations with 
documented composition and action. (Level D)
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RECOMMENDED DOSES OF FOLATE 
SUPPLEMENTATION DURING THE 
PRECONCEPTION PERIOD, PREGNANCY  
AND LACTATION (TABLE 1)
A group at low risk of fetal defects  
and pregnancy complications 
Randomized, cohort and observational studies have 
shown a reduction in the risk of neural tube defects in wo-
men taking a daily supplement containing 0.4 to 0.8 mg 
of folic acid. According to the principle of using the lowest 
effective dose, women who are not at risk of folate metabo-
lism disorders are recommended to take 0.4 mg of folic acid 
during the preconception period, pregnancy and lactation. 
Recommendation
Women in the low-risk group are recommended to 
take supplements containing 0.4 mg of folate per 
day. (Level B)
A group at increased risk of fetal defects  
and pregnancy complications 
The occurrence of fetal defects, IUGR and preeclampsia 
in the previous pregnancy, may indicate an increased risk of 
folate deficiency or folate metabolism disorders. This group 
of women is recommended to take a double dose of folic 
acid including active forms of folate.
Frequent occurrence of defects in the nervous system 
has also been observed in fetuses of women with type 1 and 
type 2 diabetes [21]. It seems that both hyperglycemia and 
insulin resistance may interfere with folate metabolism. 
Cohort analysis has indicated a lower percentage of neural 
tube defects in women with pre-gestational diabetes mel-
litus taking supplements containing more than 0.4 mg of 
folic acid [21]. Special attention should be paid to women 
with polycystic ovary syndrome using metformin. It has 
been reported that deficiency of folate and vitamin B12 du-
ring metformin therapy results in elevated homocysteine 
levels [22].
Folate deficiency and an increased risk of neural tube 
defects may be associated with chronic gastrointestinal 
diseases (colitis ulcerosa, coeliac disease, Crohn’s disease) 
that interfere with absorption. Vitamin deficiencies, inclu-
ding folate deficiency, also occur in women after bariatric 
surgery [23].
Spina bifida also occurs more frequently in obese wo-
men. Studies on folic acid supplementation in this group of 
Table 1. Recommended doses in individual groups at risk of fetal defects
Low-risk group Increased-risk group High-risk group
0.4 mg/day 
within 12 weeks before 
planned pregnancy, during 
pregnancy and lactation
0.8 mg/day 
including active folate and vitamin B12  
within 12 weeks before planned pregnancy,  
during pregnancy and lactation
5 mg/day
including active folate and vitamin B12  
within 12 weeks before planned pregnancy  
and in the first trimester of pregnancy  
0.8 mg/day 
in the second and third trimesters and during lactation
Healthy women without 
their own and family 
history of fetal defects
Fetal defects in the patient’s or the closest family history 
Neural tube defects in the mother, father  
or their offspring
IUGR or/and preeclampsia in the history
Pre-gestational diabetes type 1 or 2
Digestive diseases:
Colitis ulcerosa 
Crohn’s disease 
Coeliac disease
Hepatic failure
Renal failure — dialysis
Condition after bariatric surgery
Obesity
Drugs:
Anti-epileptics  
Metformin  
Methotrexate  
Cholestyramine  
Sulfasalazine
Stimulants:
Smoking 
Alcoholism
Decreased MTHFR activity
635
Dorota Bomba-Opoń et al., Folate supplementation during the preconception period, pregnancy and puerperium
www. journals.viamedica.pl/ginekologia_polska
women show lower efficacy of routine supplementation in 
a group with BMI greater than 24 and a significantly lower 
risk of spina bifida in children of obese women with high 
levels of red cell folate [24, 25].
Antiepileptic drug therapy is a risk factor for reduced 
serum levels of folate in women and supplementation with 
folic acid during the preconception period may have a bene-
ficial effect on reducing the risk of deficiency. However, the 
use of high doses, especially above 5 mg, is unreasonable 
and may lead to a reduction in seizure threshold [26].
Impaired folic acid metabolism and impaired remethyla-
tion of homocysteine to methionine, resulting in increased 
homocysteine levels and decreased plasma folate levels, 
may be due to reduced methylthetrahydrofolate reductase 
(MTHFR) activity [27]. There are over 40 types of MTHFR poly-
morphisms, the most common of which are C677T, A1298C 
and G1793A. MTHFR 677 C > T is the most common and the 
best described of them; its frequency varies according to 
population: in Asian population, the frequency of homo-
zygous dominant individuals ranges from 10% to 15% and 
heterozygous dominant individuals is up to 50%; in Europe, 
the frequency of homozygous dominant individuals ranges 
from 8% to 18% , and in Poland, it is from 5% to 11% [27]. This 
results in a protein with reduced enzymatic activity — about 
70% for homozygous genotypes TT and about 40% for hete-
rozygous genotypes CT. The results of studies conducted in 
non-pregnant female carriers of different MTHFR genotypes 
have shown that active forms of folate have increased plasma 
folate concentrations significantly more than folic acid [28]. 
Increased supply of folate in pregnancy can mask vitamin 
B12 deficiency and at the same time increase metabolic di-
sorders leading to hyperhomocysteinaemia [18]. Therefore, 
it is recommended that supplementation wi`th particularly 
higher folate doses be supplemented with vitamin B12. 
Recommendation
Women in the increased-risk group are recommen-
ded to take supplements containing 0.4 mg of folate 
per day and an additional 0.4 mg, preferably of active 
folate, per day. Supplements additionally enriched 
with vitamin B12 are recommended. (Level C)
A group at high risk of fetal defects  
and pregnancy complications
Neural tube defects may be related to genetic disorders 
of folate metabolism and chromosomal abnormalities. Re-
search results confirm that the use of folic acid supplemen-
tation before pregnancy reduces the risk of reoccurrence by 
up to 85% [29]. Unfortunately, only 35% of women in whose 
offspring a neural tube defect reoccurred took preparations 
containing folate [30]. Currently there are no studies confir-
ming that empirically recommended high doses of folate 
are effective. However, due to the high risk of defects, most 
panel experts recommend doses of 4 to 5 mg during the 
preconception period and the first trimester of pregnancy. 
Considering the possibility of negative effects of high doses 
of folate on the fetus in the next trimesters of pregnancy, the 
dose should be reduced to 0.8 mg after the first trimester of 
pregnancy and continued until the end of lactation. 
Recommendation
Women in the high-risk group are recommended to 
take 5 mg of folate per day including active forms 
of folate and vitamin B12 during the preconcep-
tion period and the first trimester of pregnancy. 
The dose of folate should be reduced to 0.8 mg per 
day during the next trimesters of pregnancy and 
lactation. (Level D)
Table 2. Recommendations of the Polish Society of Gynaecologists 
and Obstetricians (PTGP): Folate supplementation during the 
preconception period, pregnancy and puerperium
1. All women of childbearing age should include in their diet foods 
rich in folate (lettuce, spinach, cabbage, broccoli, whole grains, 
liver, eggs, nuts and cheeses) and fortified foods. (Level B)
2. When planning a pregnancy, women of childbearing age should 
additionally use folate supplementation for at least 12 weeks be-
fore conception. (Level B)
3. Women should continue to use folate supplementation through-
out their pregnancy, puerperium and lactation period. They 
should use preparations with documented composition and ac-
tion. (Level D)
4. Women in the low-risk group are recommended to take supple-
ments containing 0.4 mg of folate per day (Level B).
5. Women in the increased-risk group are recommended to take 
supplements containing 0.4 mg of folate per day and an addi-
tional 0.4 mg, preferably of active folate, per day. Supplements ad-
ditionally enriched with vitamin B12 are recommended (Level C).
6. Women in the high-risk group are recommended to take 5 mg of 
folate per day including active forms of folate and vitamin B12 dur-
ing the preconception period and the first trimester of pregnancy. 
The dose of folate should be reduced to 0.8 mg per day during the 
next trimesters of pregnancy and lactation (Level D).
Table 3. Strength of recommendations
Level A — recommendations are based on evidence obtained from 
randomized, controlled trials
Level B — recommendations are based on evidence obtained from 
controlled trials without randomization
Level C — recommendations are based on evidence obtained from 
cohort or case–control analytic studies and from multiple time 
series with or without  the intervention
Level D — recommendations are based on  expert committee 
reports or opinions or clinical experience of respected authorities
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